Immunotherapy is a form of helping the body’s immune system to identify cancer cells as foreign. Once the body can recognise the cancer cells, the immune system can mount reaction against these cells, thus hindering the growth and development of a tumour.

The technology was developed at the Bill Walsh Translational Cancer Research Laboratory, part of the Kolling Institute of Medical Research at Royal North Shore Hospital in Sydney. Regeneus has secured the exclusive worldwide rights to the human and animal applications of the therapeutic cancer vaccine technology.

Strategic Partners

We have partnered with Northern Cancer Institute in Sydney for the Phase I clinical trial in humans for RGSH4K.

We have partnered with Small Animal Specialist Hospital (SASH) in Sydney for the lymphoma trial for canines for Kvax.